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surgical cosmesis were more likely to develop photographically as-
sessed breast shrinkage (OR 1.54, 95% CI 1.21-1.96; p<0.001), tumour 
bed induration (OR 1.80, 95% CI 1.43-2.26; p<0.001) and sub-optimal 
cosmesis (OR 8.15, 95% CI 6.08-10.92; p<0.001) at five years. 
Conclusions: Improved dose homogeneity with IMRT translates into 
superior overall cosmesis and reduces the risk of skin telengiectasia at 
5 years post RT. These results are practice-changing and should 
encourage other centres still using 2D standard RT to implement 
breast IMRT. In addition, surgical cosmesis should be optimised as this 
also has a significant effect on late breast toxicities. 
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Purpose/Objective: Radiation therapy (RT) significantly ameliorates 
local control in breast cancer (BC) patients treated with breast 
conserving surgery and in high relapse risk radically resected patients. 
Some debate exist about the value of RT in elderly patients. In this 
retrospective analysis on a single institution series of BC patients we 
evaluate local control as regard to age and different prognostic 
factors. 
Materials and Methods: Patients undergoing postoperative RT for 
localized breast cancer treated at our institution between January 
1999 and December 2008 were the object of the study. RT consisted 
of 50 Gy in 5 weeks on the chest wall, in the case of mastectomy, and 
on residual breast in the case of quadrantectomy or lumpectomy, and 
eventually on the axillar and supraclavear nodes. A boost of 10Gy was 
administered to the tumor bed of all the conserving surgery treated 
patients. The clinical data were analyzed with univariate and 
multivariate analysis considering age (<40, 40-64, ≥65), nodal status 
(N + vs N-), tumor classification (T1 vs >T1), grading (G1–2 vs G3), 
oestrogen and progesterone receptors (ER and PgR), and erb-B2 
status. A further classification of patients according to a surrogate 
approximate genetic signature and recognizing the four subtypes of 
BC, namely luminal A (ER + and/or PgR + , and erb-B2–), luminal B 
(ER+ and/or PgR + , and erb-B2 + ), HER-2 (ER-, PgR– and erb-B2 + ), 
and basal(ER–, PgR– and erb-B2–) was adopted. Freedom from loco-
regional relapse (FFLR) was defined as the time from diagnosis to the 
loco-regional relapse (LR). The 8-year LR rate was estimated by the 
Kaplan-Meier method. 
Results: Seven hundred thirty-three patients with a median age of 53 
years (range 27-84) and with a minimum follow up of 12 months 
entered the study. Chemotherapy, hormonal therapy or both, were 
administered at 57, 374, and 249 patients, respectively. The median 
follow up was 84 months (range 12 – 126), with an overall survival of 
96%. The 8-year actuarial rate of LR was 3%. Univariate analysis 
showed a significant relation of LR with age (LR=6.1% for age<40 
years, LR=1.6% for 40≤age<65, LR=6.5% forage ≥65), grading (LR=1.7% 
for G1–2, LR=4.1% for G3), ER status (LR=2.3% forER-, LR=5.4% for ER+) 
and HER2 subtype (LR=2.3% for no-HER2, LR=8.5% for HER2). From the 
multivariate analysis, age (hazard risk 3.9 for age≥65 years and 3.2for 
age<40 years compared with 40≤age<65) and HER2 subtype (hazard 
risk3.8) were the only significant factors for LR risk prediction (Fig.1). 
 
Figure 1 
 
  
Conclusions: Age less than 40 and equal to or more than 65 years and 
HER-2 subtype are associated with a greater risk of local relapse. 
These results do not support a different RT management of elderly 
patients.  
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Background: Although radiotherapy is a very cost-effective treatment 
modality, it requires major investments for building and equipment. 
Adequate planning of radiotherapy infrastructure and personnel may 
prevent waiting lists and overcapacity with vacancies. In the 
Netherlands, until recently, radiotherapy capacity was regulated by 
the government. Until 2000 this was done by a limitation of the 
number of linear accelerators and since then by a limitation of the 
number of centers. Models have been used to estimate the expected 
number of cancer patients, patients requiring radiotherapy and the 
distribution over different types of treatment (simple, standard, 
intensive, or special). This was used to determine the required 
number of machines and staffing. The actual situation in the 
Netherlands is evaluated annually by a survey of all Dutch centers. 
Materials and methods: For the period from 1998 to 2010, the 
predictions from the Dutch Society of Radiotherapy and Oncology 
were compared with the actual measures from annual surveys of the 
21 Dutch centers. In addition, developments of productivity and 
departments size are evaluated. 
Results: An annual increase in the number of patients and 
radiotherapy treatments of 3.5-4.0 % was observed. The number of 
machines and staffing increased accordingly. After a relative increase 
in the percentage of 3D conformal treatments in the late 1990s and 
early 2000s, a shift from 3D-conformal techniques to intensity 
modulated, image-guided and stereotactic techniques was seen in the 
later years. In 2010, 39% of the treatment series was delivered using 
IMRT, IGRT, SBRT or radiosurgery techniques, 21% using 3D-conformal 
techniques an 40% using standard techniques. In 1998, their were 274 
treatment series per radiation oncologist, 625 per physicist and 532 
per linear accelerator, compared to 249 series per radiation 
oncologist, 540 per physicist and 451 per accelerator in 2010.  
The number of radiotherapy departments did not increase over the 
study period. The average size of the centers was 5.7 accelerators, 
10.4 fte radiation oncologists, 4.8 fte clinical physicists and 45.8 fte 
technologists, compared to 3.2 accelerators and 6.2 fte, 2.7 fte and 
30.4 fte, respectively in 1998.  
Discussion: Prognoses of the number and types of radiotherapy 
treatments allow for an accurate prediction and planning of the 
required staffing and infrastructure to avoid waiting lists and 
overcapacity. The expansion of the existing departments instead of 
the addition of new centers, allows for a more rapid implementation 
of new techniques and will allow sufficient sub-specialization of the 
staff. In recent years, the expansion of departments is often realized 
by establishing ‘satellite centers’, which are an integral part of the 
main center. Treatment planning is performed at the main site and 
the staff rotates over the satellite(s) and the main center. 
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Historically, England has faced an under-provision of radiotherapy, 
due in part to the decentralised nature of equipment procurement 
and workforce management. The ESTRO QUARTS report showed that 
England operated just over 50% of the estimated number of 
megavoltage radiotherapy units estimated as necessary for treatment 
of cancer in the population. 
In 2007 the National Radiotherapy Advisory Group’s report was 
commissioned by Prof. Mike Richards, National Cancer Director. It 
suggested that a 63% increase was required to bridge the gap between 
actual radiotherapy activity (30,000 fractions per million/year) and 
optimum treatment levels(48,000 fractions per million/year). 
Projections of treatment activity suggested that by 2016, activity 
levels of 54,000 fractions per million/year would be required. The 
report recommended a long term strategy for the development and 
expansion of a multi-professional workforce for radiotherapy delivery, 
the expansion and modernisation of radiotherapy delivery services,the 
central collection of radiotherapy treatment statistics, and 
improvement in treatment quality starting with IMRT and moving over 
a decade to 4-D adaptive radiotherapy. A National Radiotherapy 
